The AI Pharmaceutical Industry Ushers in a Window of Rapid Development

The high investment, long cycle, and high failure rate of new drug R&D have always been inescapable pain points for the biopharmaceutical industry. AI technology is rewriting the R&D logic of traditional pharmaceutical companies. Currently, AI can compress the preclinical R&D cycle of new drugs to approximately one year, and multiple AI-designed drugs globally have entered Phase II and Phase III clinical trials, with the industry accelerating into a harvest period. Data predicts that from 2025 to 2030, China's intelligent pharmaceutical market is expected to exceed 500 billion yuan. Documents from the Ministry of Industry and Information Technology also indicate that AI technology is deeply integrating into the entire drug R&D chain. Driven by policy dividends and capital support, the AI pharmaceutical industry has entered a window of rapid development.


Facing the opportunities of industrial transformation, traditional pharmaceutical companies are proactively embracing the wave of intelligence, accelerating their layout in the "AI + Pharma" track through strategic partnerships, internal system development, and other approaches. Among these, strong alliances between pharmaceutical companies and AI biotechnology firms have become an important model—jointly building AI-driven R&D platforms, jointly conducting key technology research, jointly advancing achievement translation, and jointly creating an open innovation ecosystem.

The encounter of AI and siRNA is opening a technological window with even greater imagination. If small molecules and antibodies are the "first battlefield" of AI pharma, then nucleic acid drugs represented by small interfering RNA (siRNA) constitute a "second battlefield" with a higher degree of fit between AI capabilities and emerging modalities.

The core advantage of siRNA drugs lies in "silencing disease-causing proteins from the genetic source." Their design is essentially a sequence-space optimization problem: for the same target gene mRNA, there exist thousands of possible siRNA sequences, and each sequence can be further combined with different chemical modification patterns, causing the candidate space to expand exponentially. Traditional R&D relies on extensive in vitro screening experiments for trial-and-error, which is inefficient and costly. AI's strength lies precisely in handling high-dimensional, sparse, small-sample data pattern recognition problems—exactly the typical scenario for siRNA activity prediction.

Global industry actions are even more aggressive. In June 2026, Alnylam reached a partnership with AI company Inceptive worth up to $2 billion, with the core goal of using generative AI models to accelerate siRNA sequence design and the exploration of novel chemical modifications. Alnylam possesses over 20 years of proprietary siRNA data, and Inceptive's foundation models "discovered meaningful biological insights within weeks" in the joint exploration. This signals that leading players in the siRNA field have upgraded AI from an "efficiency tool" to a "design engine."

Entrogen Biotech focuses on key AI technologies in small nucleic acid drug R&D, committed to building a full-process AI R&D platform for small nucleic acid drugs covering target discovery, sequence and modification design, delivery vector design, and druggability evaluation. As technology continues to iterate, AI will reshape the discovery process of small nucleic acid drugs, advancing the translation of small nucleic acid drug pipelines faster, better, and more intelligently.